109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
糖尿病足溃疡干细胞治疗的进展
Authors Wang B, Zhao G, Zhang J, Chen W, Yang S, Sun Y
Received 5 September 2025
Accepted for publication 21 October 2025
Published 29 October 2025 Volume 2025:18 Pages 4021—4034
DOI https://doi.org/10.2147/DMSO.S564011
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Halis Akturk
Bin Wang,1,2 Gang Zhao,2,3 Jiaqi Zhang,4 Wenyu Chen,2 Shanshan Yang,1 Yinuo Sun1
1Department of Surgery, The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang, 150040, People’s Republic of China; 2First Clinical Medical College, Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang, 150040, People’s Republic of China; 3Department of Peripheral Vascular Surgery, The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang, 150040, People’s Republic of China; 4Department of Pharmaceutical Engineering, Harbin Labor Technician College, Harbin, Heilongjiang, 150500, People’s Republic of China
Correspondence: Gang Zhao, Email zhaogang1120@126.com
Abstract: Diabetic foot ulcers (DFU) are a severe and recurrent complication of diabetes that significantly increase the risk of infection, amputation, and mortality. Conventional therapies often fail to achieve complete healing due to the complex microenvironment characterized by ischemia, chronic inflammation, neuropathy, and oxidative stress. Stem-cell-based interventions offer a multifaceted therapeutic strategy by promoting angiogenesis, modulating immune responses, reducing oxidative damage, and enhancing extracellular matrix remodeling. This review provides a comprehensive analysis of major stem-cell sources including bone marrow-derived mesenchymal stem cells (BM-MSCs), adipose-derived stem cells (ADSCs), umbilical cord blood mesenchymal stem cells (UCB-MSCs), and induced pluripotent stem cells (iPSCs). Comparative evaluation highlights that ADSCs are advantageous for autologous use and easy harvesting, BM-MSCs have the longest clinical track record, UCB-MSCs offer low immunogenicity for allogeneic applications, and iPSCs provide customizable options but require genomic stability monitoring. Increasing evidence supports the use of cell-free approaches, particularly exosome and secretome-based therapies, which reproduce stem-cell paracrine effects while minimizing ethical and safety concerns. Integration of these biologics with advanced biomaterials and nanoplatforms further enhances local retention, controlled release, and wound microenvironment regulation. Despite encouraging results, challenges remain in standardizing cell preparation, optimizing dosage and delivery, and ensuring long-term safety and cost-effectiveness. Future directions include harmonizing clinical protocols, expanding exosome-based therapeutics, and conducting large multicenter trials to validate their efficacy in real-world DFU management.
Keywords: diabetic foot ulcer, stem cell therapy, mechanism of action, clinical application, diabetes, wound
1Department of Surgery, The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang, 150040, People’s Republic of China; 2First Clinical Medical College, Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang, 150040, People’s Republic of China; 3Department of Peripheral Vascular Surgery, The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang, 150040, People’s Republic of China; 4Department of Pharmaceutical Engineering, Harbin Labor Technician College, Harbin, Heilongjiang, 150500, People’s Republic of China
Correspondence: Gang Zhao, Email zhaogang1120@126.com
Abstract: Diabetic foot ulcers (DFU) are a severe and recurrent complication of diabetes that significantly increase the risk of infection, amputation, and mortality. Conventional therapies often fail to achieve complete healing due to the complex microenvironment characterized by ischemia, chronic inflammation, neuropathy, and oxidative stress. Stem-cell-based interventions offer a multifaceted therapeutic strategy by promoting angiogenesis, modulating immune responses, reducing oxidative damage, and enhancing extracellular matrix remodeling. This review provides a comprehensive analysis of major stem-cell sources including bone marrow-derived mesenchymal stem cells (BM-MSCs), adipose-derived stem cells (ADSCs), umbilical cord blood mesenchymal stem cells (UCB-MSCs), and induced pluripotent stem cells (iPSCs). Comparative evaluation highlights that ADSCs are advantageous for autologous use and easy harvesting, BM-MSCs have the longest clinical track record, UCB-MSCs offer low immunogenicity for allogeneic applications, and iPSCs provide customizable options but require genomic stability monitoring. Increasing evidence supports the use of cell-free approaches, particularly exosome and secretome-based therapies, which reproduce stem-cell paracrine effects while minimizing ethical and safety concerns. Integration of these biologics with advanced biomaterials and nanoplatforms further enhances local retention, controlled release, and wound microenvironment regulation. Despite encouraging results, challenges remain in standardizing cell preparation, optimizing dosage and delivery, and ensuring long-term safety and cost-effectiveness. Future directions include harmonizing clinical protocols, expanding exosome-based therapeutics, and conducting large multicenter trials to validate their efficacy in real-world DFU management.
Keywords: diabetic foot ulcer, stem cell therapy, mechanism of action, clinical application, diabetes, wound